NEW YORK and WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the company’s participation in four upcoming investor conferences. Marino Garcia, CEO of Dianthus Therapeutics, will participate in fireside chats and host one-on-one investor meetings at the following conferences: Guggenheim 2nd Annual Healt ...